Skip to content

Long-term survival outcomes in patients with HR+/Her2-, stage IIA-IIIA breast cancer treated with adjuvant chemotherapy versus neoadjuvant chemotherapy: a real-world study

Long-term survival outcomes in patients with HR+/Her2-, stage IIA-IIIA breast cancer treated with adjuvant chemotherapy versus neoadjuvant chemotherapy: a real-world study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400083063
Enrollment
Unknown
Registered
2024-04-15
Start date
2024-04-15
Completion date
Unknown
Last updated
2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Female patients with unilateral invasive breast cancer (ductal carcinoma/lobular carcinoma) diagnosed as HR+, Her2- by IHC. 2) The Pathology Department of the First Affiliated Hospital of Chongqing Medical University conducts central pathological examination on tumor specimens. 3) At the time of diagnosis, the anatomical staging was stage II-IIIA, with no evidence of distant metastasis. 4) Age range from 20 to 70 years old 5) Surgery and chemotherapy are performed in our hospital, or standard systematic treatment that meets current diagnostic and treatment standards is completed in an external hospital. 6) Do not have other malignant tumors. 7) There is no history of breast cancer in the past.

Exclusion criteria

Exclusion criteria: 1) Carcinoma in situ or inflammatory breast cancer 2) Receiving targeted therapy 3) Incomplete or irregular standardized treatment cycles 4) Special types of cancer include mucinous carcinoma or myeloid carcinoma. 5) HER2 2+ without FISH results 6) Tumor information is missing, making it impossible to obtain tumor imaging information.

Design outcomes

Primary

MeasureTime frame
Overall survival;Disease-free survival;

Countries

China

Contacts

Public ContactQiao Cheng

The First Affiliated Hospital of Chongqing Medical University

chengqiao@hospital.cqmu.edu.cn+86 130 9879 4661

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026